NeuroSolutions Limited (“NeuroSolutions”) was founded and incorporated in 2001 as a “spin-out” company from the University of Warwick in the UK. NeuroSolutions is a neuroscience and neurology-based translational research and development company.
For nearly 15 years, NeuroSolutions Ltd has been a leading Contract Research Organisation (CRO) providing high quality electrophysiological services to the Pharmaceutical and Biotechnology industry, with management having a combined experience of over 80 years in electrophysiological research and drug development within this sector. The company was established to position itself as a leading provider of specialised electrophysiology services to the biopharmaceutical industry. We use our technology to support all aspects of preclinical drug discovery and biomedical translational research with a particular focus on disease of the nervous system. The company supports research and development focused on pain, neurodegenerative disorders, psychiatric disorders, anxiety, depression and central neural control of bodyweight, specifically obesity.
Professor David Spanswick
David has over 30 years of experience in electrophysiology and neuroscience. He graduated from the University of East Anglia, UK in 1986 (B.Sc). He then obtained his PhD at University of Birmingham, studying neurophysiology. Prior to establishment of NeuroSolutions, Prof. Spanswick acted as a consultant to a number of multinational pharmaceutical companies. Prof. Spanswick is the author of over 50 academic publications in his area of expertise. In addition to his role as Chief Scientific Officer with NeuroSolutions Ltd, Dave was appointed a senior lecturer, University of Warwick in 2000 and Professor of Molecular Neuroscience at Warwick Medical School in 2004. In 2011 Dave joined the Department of Physiology at Monash University.
Dr Fei-Yue Zhao
Dr Zhao is a co-founder of NeuroSolutions and has been Technical Officer since establishment. Dr Zhao is an internationally recognised expert in pain research, having worked previously in laboratories in the UK and Japan. Dr Zhao has over 30 years’ experience in system electrophysiology and had worked in multiple drug discovery programs in the pain area since 1999. Prior to joining NeuroSolutions, Dr Zhao was head of system electrophysiology at Parke Davis/Pfizer in Cambridge, UK where he worked on the site and mechanism of action of Gabapentin.